Insights to power better bladder cancer care.
We are collecting some of the most robust clinical data and largest observational cohorts ever obtained in urothelial cancer to further expand the clinical utility of UroAmp beyond detection, monitoring, and prediction. Our published data is highly compelling, but we are committed to doing even more.
CAP I 2022
Urinary comprehensive genomic profiling: correlating urothelial carcinoma mutation with clinical risk and efficacy of intervention
AUA I 2022
Urinary comprehensive genomic profiling predicts clinical recurrence in patients undergoing surveillance for urothelial carcinoma
AUA I 2022
Urine comprehensive genomic profiling predicts recurrence in patients with non-muscle invasive bladder cancer treated with intravesical therapy carcinoma
SUO I 2022
Urine comprehensive genomic profiling of urothelial carcinoma patients undergoing intravesical therapy enables detection of actionable DNA mutations associated with drug response and risk stratification
ASCO GU I 2022
Comprehensive genomic profiling of urine DNA for urothelial carcinoma detection and risk prediction
Journal of Clinical Medicine I 2022
Urinary comprehensive genomic profiling correlates urothelial carcinoma mutations with clinical risk and efficacy of intervention
This study is powered to allow evaluation of many less common and fascinating populations of patients within the spectrum of bladder cancer, from diagnosis through treatment. The INSITE study will power deep evidence of UroAmp’s disease classification algorithms and genomic risk insights across diverse patient populations, time points, pathologic subtypes, and many other sub-analyses. Strength of the INSITE data will grow with long-term sample collections and monitoring of patient outcomes.
The CURE study is a broad development and validation study enrolling patients with diverse clinical scenarios and abnormalities.
This study design is intended to prove our ability to detect multiple types of cancer from urine. CURE patients have been enrolled from urology offices with broad inclusion criteria. Many of these scenarios, such as infection and recent instrumentation, are direct contraindications to previous technologies. The CURE study will validate multi-cancer detection in a broad group of patients with diverse clinical co-morbidities and other.
We are committed to empowering our biopharmaceutical partners to assist them in delivering breakthrough therapeutics in precision oncology. Our technology can be used to inform trial design, identify ideal patients, and measure response and resistance to targeted therapeutics, potentially accelerating trial enrollment and improving program success rates.